云南高校图书馆联盟文献共享服务平台- SUBTILISIN

SUBTILISIN: 作品数：42被引量：159H指数：7; 导出分析报告; 相关领域：医药卫生更多>>; 相关作者：王成涛曹雁平籍保平孙宝国闫俊鹏更多>>; 相关机构：北京工商大学中国农业大学武汉大学上海东之汇生物科技有限公司更多>>; 相关期刊：《Chinese Medical Journal》《World Journal of Cardiology》《Signal Transduction and Targeted Therapy》《World Journal of Diabetes》更多>>; 相关基金：国家自然科学基金国家重点基础研究发展计划国家教育部博士点基金国家高技术研究发展计划更多>>

The Impact of PCSK9 on Risk Factors for Ischemic Stroke and Potential Mechanisms: 《American Journal of Molecular Biology》2025年第1期110-122,共13页Zehua He Mingtian Lu Zhejing Ding Zhengwei Chen Tianyang Guan Zhongliang Li Cheng Zhou Haiquan Tao Guangsen Cheng Yu Liu; Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proprotein convertase (PCs) family, which facilitates the degradation of low-density lipoprotein receptors (LDL-R) via intracellular and cell su...; 关键词：Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Ischemic Stroke ATHEROSCLEROSIS INFLAMMATION

Research on Hepatocyte Regulation of PCSK9-LDLR and Its Related Drug Targets: 《Chinese Journal of Integrative Medicine》2024年第7期664-672,共9页LIU Su-su YU Tong QIAO Yan-fang GU Shu-xiao CHAI Xin-lou; Supported by National Science and Technology Major Special Project Based on Big Data Research and Development of New Chinese Medicine Drugs(No.2019ZX09201004-001-021)。; The prevalence of hyperlipidemia has increased significantly due to genetic, dietary, nutritional and pharmacological factors, and has become one of the most common pathological conditions in humans. Hyperlipidemia ca...; 关键词：HYPERLIPIDEMIA proprotein convertase subtilisin/kexin type 9 low-density lipoprotein receptor intracellular pathway extracellular pathway

Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease:A review of efficacy,safety,and outcomes: 《World Journal of Cardiology》2024年第7期397-401,共5页Moiud Mohyeldin Ahmed S Abuelgasim Ahmed MG Mustafa; Peripheral artery disease(PAD)is a common condition characterized by atherosclerosis in the peripheral arteries,associated with concomitant coronary and cerebrovascular diseases.Proprotein convertase subtilisin/kexin ...; 关键词：Peripheral artery disease Proprotein convertase subtilisin/kexin type 9 inhibitors Cardiovascular risk reduction Evolocumab Alirocumab Lipid-lowering therapy Major adverse limb events Clinical outcomes COST-EFFECTIVENESS Safety profile

Targeting proprotein convertase subtilisin/kexin type 9(PCSK9):from bench to bedside被引量：6: 《Signal Transduction and Targeted Therapy》2024年第2期509-557,共49页Xuhui Bao Yongjun Liang Hanman Chang Tianji Cai Baijie Feng Konstantin Gordon Yuekun Zhu Hailian Shi Yundong He Liyi Xie; supported by the National Natural Science Foundation of China(No.82272817,to X.B.);Shanghai Pujiang Program(No.22PJ1412400,to X.B.,and No.22PJ1402700,to Y.H.);Science and Technology Development Fund of Shanghai Pudong New Area(No.PKJ2022-Y50,to X.B.).; Proprotein convertase subtilisin/kexin type 9(PCSK9)has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases(CVD).This...; 关键词：PCSK9 METABOLISM CONVERT

Association of Remnant-like Particle Cholesterol with Major Adverse Cardiovascular Events in Subjects with Different Levels of Proprotein Convertase Subtilisin/Kexin 9:A 9.5-year Follow-up Study in a Beijing Community Population: 《Cardiology Discovery》2023年第3期159-165,共7页Xiaona Wang Ruping Tie Ruihua Cao Xu Yang Wenkai Xiao Li Sheng Ping Ye; supported by the National Key Research and Development Program of China (2021YFC2500604)to Li Sheng.; Objective::The purpose of this study was to determine the relationship between remnant-like particle cholesterol(RLP-C)and major adverse cardiovascular events(MACEs)in patients with different levels of proprotein conv...; 关键词：Cardiovascular diseases Remnant-like particle cholesterol Proprotein convertase subtilisin/kexin 9 Major adverse cardiovascular events

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering:current evidence,clinical implications,and future perspectives被引量：1: 《Chinese Medical Journal》2023年第6期645-652,共8页Xin Zhou Ziping Li Hangkuan Liu Yongle Li Dong Zhao Qing Yang; National Key Research and Experimental Development Program of China(Nos.2020YFC2004700 and 2020YFC2004706);the National Natural Science Foundation of China(No.81970304);the Tianjin Municipal Science and Technology Commission(No.18ZXZNSY00290); The clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors(PCSK9i)in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease(ASCVD)has been well establishe...; 关键词：Cholesterol-lowering drugs BLEEDING ANTITHROMBOTIC LDL cholesterol Proprotein convertase subtilisin/kexin type 9 inhibitors

Proprotein convertase subtilisin/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization:A case report被引量：1: 《World Journal of Clinical Cases》2022年第19期6728-6735,共8页Liu Yang Yan-Yan Xiao Liang Shao Chang-Sheng Ouyang Yao Hu Bin Li Li-Feng Lei Hong Wang; the Doctor Start-up fund of Jiangxi provincial People's Hospital,The First Affiliated Hospital of Nanchang Medical College,No.19-236.; BACKGROUND Familial hypercholesterolemia(FH)is an autosomal dominant disorder that is characterized by severely increased low-density lipoprotein(LDL)cholesterol levels.At the same time,elevated LDL levels accelerated...; 关键词：Coronary artery disease Familial hypercholesterolemia Low-density lipoprotein receptor mutation Non response Proprotein convertase subtilisin/kexin type 9 inhibitor

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia被引量：1: 《Chinese Medical Journal》2022年第6期730-731,共2页Yanren Peng Danxia Guo Sijie Jiang Hua Zheng; To the Editor:The proprotein convertase subtilisin/kexin type 9(PCSK9)-inhibitor,evolocumab,can bind with PCSK9 in plasma and reduce the degradation of the PCSK9-low density lipoprotein(LDL)receptor complex,thereby re...; 关键词：PATIENTS LIPOPROTEIN CONVERT

Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway被引量：4: 《Cancer Biology & Medicine》2022年第1期90-103,共14页Mingyan He Jing Hu Tingting Fang Wenqing Tang Bei Lv Biwei Yang Jinglin Xia; supported by grants from the National Natural Science Foundation of China(Grant No.81802461);the Jiangxi Provincial Department of Science and Technology(Grant No.20202ACBL216012);the Education Department of Jiangxi Province(Grant No.GJJ170010)。; Objective:Protein convertase subtilisin/Kexin type 9(PCSK9)has been found to be closely associated with the occurrence and development of numerous tumors.However,the precise role of PCSK9 and its relationship to the d...; 关键词：Hepatocellular carcinoma GROWTH PCSK9 GSTP1 JNK

Lowering low-density lipoprotein cholesterol: from mechanisms to therapies被引量：3: 《Life Metabolism》2022年第1期25-38,共14页Jie Luo Jin-Kai Wang Bao-Liang Song; This work was supported by grants from the Ministry of Science and Technology(2018YFA0800703);the National Natural Science Foundation(91957103,31690102,32021003,and 91957208).B.-L.Song acknowledges the support from the Tencent Foundation through the XPLORER PRIZE.; Low-density lipoprotein(LDL)is the main carrier of cholesterol and cholesteryl ester in circulation.High plasma levels of LDL cholesterol(LDL-C)are a major risk factor of atherosclerotic cardiovascular disease(ASCVD)....; 关键词：CHOLESTEROL low-density lipoprotein STATIN EZETIMIBE proprotein convertase subtilisin/kexin type 9 atherosclerotic cardiovascular disease

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

SUBTILISIN

检索结果分析

下载全文

高级检索检索式检索

时间限定

期刊范围

学科限定全选

高级检索 检索式检索

时间限定

期刊范围

学科限定全选

SUBTILISIN

检索结果分析

下载全文

用户登录

高级检索检索式检索